/PRNewswire/ Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases, announced that it has submitted to.
FDA advisory panel urges Pfizer COVID vaccine for children 5 to 11 usatoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usatoday.com Daily Mail and Mail on Sunday newspapers.
Some adults may get a 4th COVID shot; COVAXIN US trials: Updates azcentral.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from azcentral.com Daily Mail and Mail on Sunday newspapers.
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
Home / Top News / Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19
Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant
Adverse events reported were similar to placebo, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events
MALVERN, Pa., and HYDERABAD, India, July 02, 2021 (GLOBE NEWSWIRE)